Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Resected NSCLC (SIRN)
2006-006566-42Phase 2Terminated
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in non-small cell lung cancer (NSCLC), sponsored by Johannes Gutenberg University Mainz. Primary endpoint: Progression-free survival at 2 years. Started Aug 2007; status: terminated.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-006566-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006566-42.